Project acronym CM TURNOVER
Project Uncovering the Mechanisms of Cardiomyocyte Differentiation and Dedifferentiation
Researcher (PI) Eldad Tzahor
Host Institution (HI) WEIZMANN INSTITUTE OF SCIENCE
Call Details Starting Grant (StG), LS4, ERC-2011-StG_20101109
Summary The quest to restore damaged organs is one of the major challenges in medicine. Recent studies in both animals and in humans suggest that the heart has a limited capacity to replenish its own cardiomyocytes (CMs) throughout life, albeit inadequate to compensate for major injuries such as acute myocardial infarction (MI). Most therapeutic research in regenerative cardiogenesis is geared toward stem cell therapy as a means to replace lost CMs associated with ischemic heart disease. Clinical data evaluating the efficacy of cell-based therapy for heart disease are relatively disappointing. This proposal encompasses multidisciplinary and novel approaches to study the molecular and cellular mechanisms that govern the proliferation, differentiation and dedifferentiation of endogenous CMs, combining developmental-, systems- and cell-biology methodologies in vitro and in vivo, in chick, rodent, and human tissue samples. First, we will perform combinatorial perturbations of signaling pathways in chick embryos, focusing primarily on the FGF-ERK pathway, to investigate the molecular switch between cardiac progenitors and CMs (Aim 1). Because adult CMs have limited proliferative capacity, mainly due to mechanical constraints, in Aim 2, we will apply state-of-the-art techniques in cell biology, to determine whether specific mechno-transduction stimuli can prime the proliferation of differentiated CMs. In order to gain deeper insights into the capacity of adult CMs to renew themselves under normal and pathological conditions, in Aim 3, we will employ a novel cell lineage methodology in mouse and human tissue, based on information encoded in genome. Using this methodology, we hope to shed light on the maintenance, renewal and regenerative capacities of adult CMs in vivo. The expected outcome will be a significantly greater understanding of the bidirectional transition from proliferating cardiac progenitors into differentiated CMs, in embryonic and adult hearts.
Summary
The quest to restore damaged organs is one of the major challenges in medicine. Recent studies in both animals and in humans suggest that the heart has a limited capacity to replenish its own cardiomyocytes (CMs) throughout life, albeit inadequate to compensate for major injuries such as acute myocardial infarction (MI). Most therapeutic research in regenerative cardiogenesis is geared toward stem cell therapy as a means to replace lost CMs associated with ischemic heart disease. Clinical data evaluating the efficacy of cell-based therapy for heart disease are relatively disappointing. This proposal encompasses multidisciplinary and novel approaches to study the molecular and cellular mechanisms that govern the proliferation, differentiation and dedifferentiation of endogenous CMs, combining developmental-, systems- and cell-biology methodologies in vitro and in vivo, in chick, rodent, and human tissue samples. First, we will perform combinatorial perturbations of signaling pathways in chick embryos, focusing primarily on the FGF-ERK pathway, to investigate the molecular switch between cardiac progenitors and CMs (Aim 1). Because adult CMs have limited proliferative capacity, mainly due to mechanical constraints, in Aim 2, we will apply state-of-the-art techniques in cell biology, to determine whether specific mechno-transduction stimuli can prime the proliferation of differentiated CMs. In order to gain deeper insights into the capacity of adult CMs to renew themselves under normal and pathological conditions, in Aim 3, we will employ a novel cell lineage methodology in mouse and human tissue, based on information encoded in genome. Using this methodology, we hope to shed light on the maintenance, renewal and regenerative capacities of adult CMs in vivo. The expected outcome will be a significantly greater understanding of the bidirectional transition from proliferating cardiac progenitors into differentiated CMs, in embryonic and adult hearts.
Max ERC Funding
1 500 000 €
Duration
Start date: 2012-01-01, End date: 2016-12-31
Project acronym MAMLE
Project Understanding the mechanisms of human acute myeloid leukaemia (AML) evolution
Researcher (PI) Liran SHLUSH
Host Institution (HI) WEIZMANN INSTITUTE OF SCIENCE
Call Details Starting Grant (StG), LS4, ERC-2016-STG
Summary Acute myeloid leukemia (AML) is one of the most deadly cancers. Currently, we do not fully understand how and why AML starts or why it tends to relapse after treatment. Recent discoveries by the applicant and others have identified preleukemic stem and progenitor cells (preL-HSPCs) as the root of AML evolution. Many healthy elderly individuals carry the preleukemic mutations in their preL-HSPCs and yet, do not develop AML. It is also becoming clearer that leukemia evolution is spanning over many years but most research is focused on the late stages of the disease.
Population genetics tools are specifically suited for the study of historical evolution however such tools are not well developed in the field of somatic evolution. This proposal will integrate population genetics, stem cell and leukemia biology in order to unravel human leukemia evolution from the very early preleukemic phase to relapse.
Novel single cell population genetics tools will be used to describe the naive clonal structure of the human hematopoietic system in both health and disease. A unique cohort of half a million Europeans, who have been followed for years, will be used to understand why only a small fraction of the individuals carrying preleukemic mutations develop AML. Novel genetic analysis will be developed to study the clonal structure of blood cells, years before AML was diagnosed. A large cohort (N=100) of AML patients were collected serially over a year and will be collected until relapse. Detailed molecular and population genetics of this cohort will aid in understanding the mechanism of AML relapse and in developing novel molecular methodologies, that will allow early relapse diagnosis. AML like many other malignancies is diagnosed late in its evolutionary path. In this proposal the evolution of AML before diagnosis and before it relapses will be studied by novel population genetic tools so that the vision of early diagnosis and treatment will become reality.
Summary
Acute myeloid leukemia (AML) is one of the most deadly cancers. Currently, we do not fully understand how and why AML starts or why it tends to relapse after treatment. Recent discoveries by the applicant and others have identified preleukemic stem and progenitor cells (preL-HSPCs) as the root of AML evolution. Many healthy elderly individuals carry the preleukemic mutations in their preL-HSPCs and yet, do not develop AML. It is also becoming clearer that leukemia evolution is spanning over many years but most research is focused on the late stages of the disease.
Population genetics tools are specifically suited for the study of historical evolution however such tools are not well developed in the field of somatic evolution. This proposal will integrate population genetics, stem cell and leukemia biology in order to unravel human leukemia evolution from the very early preleukemic phase to relapse.
Novel single cell population genetics tools will be used to describe the naive clonal structure of the human hematopoietic system in both health and disease. A unique cohort of half a million Europeans, who have been followed for years, will be used to understand why only a small fraction of the individuals carrying preleukemic mutations develop AML. Novel genetic analysis will be developed to study the clonal structure of blood cells, years before AML was diagnosed. A large cohort (N=100) of AML patients were collected serially over a year and will be collected until relapse. Detailed molecular and population genetics of this cohort will aid in understanding the mechanism of AML relapse and in developing novel molecular methodologies, that will allow early relapse diagnosis. AML like many other malignancies is diagnosed late in its evolutionary path. In this proposal the evolution of AML before diagnosis and before it relapses will be studied by novel population genetic tools so that the vision of early diagnosis and treatment will become reality.
Max ERC Funding
1 750 000 €
Duration
Start date: 2017-02-01, End date: 2022-01-31
Project acronym ONCOmetENHANCERS
Project Elucidating the Role of Enhancer Methylation Variation in Cancer and Developing Enhancer-based Markers and Targets for Precision Medicine
Researcher (PI) Asaf Hellman
Host Institution (HI) THE HEBREW UNIVERSITY OF JERUSALEM
Call Details Consolidator Grant (CoG), LS4, ERC-2016-COG
Summary Cancer is a growing medical problem which genetic and environmental basis is not clearly understood. Massive efforts over the last decade have identified differences in cancer gene expression that cannot be explained by coding sequences or promoter variations, whereas the effect of transcriptional enhancers remains unclear due to the lack of an effective way to link enhancers with their controlled genes. Recently, we discovered a class of inter-tumor, inter-patient DNA methylation variations in putative enhancers that predict changes in gene expression levels with much greater power than promoter or sequence analyses. The overall goal of this proposal is to determine if changes in enhancer methylation form part of the genomic basis of cancer. Our aim is to elucidate methylation-influenced disease regulatory circuits that affect cancer driver and risk genes and may ultimately serve as markers for disease progression and drug response. Utilizing a new genomic methodology, which allows systematic prediction and verification of gene-enhancer pairing, I will test the above hypothesis in two disease models: breast cancer and glioblastoma. I will methodologically assess numerous potential enhancers across the disease genomes and explore the effects of genetic and epigenetic mutations and variations at these sites. Informative sites will then be evaluated as markers of gene expression level in tumor biopsies. Ultimately, I will apply novel tools to manipulate selected enhancers genetically and epigenetically, thus investigating the causal relationships between enhancer methylation and gene expression, and assessing the potential for tuning gene expression levels by enhancer methylation modification. This study may transform our understanding of the mechanisms underlying disease predisposition, determine the regulatory circuits of key disease genes, lead to improved diagnosis and predictive abilities, and may pave the way for precision epigenetic therapy.
Summary
Cancer is a growing medical problem which genetic and environmental basis is not clearly understood. Massive efforts over the last decade have identified differences in cancer gene expression that cannot be explained by coding sequences or promoter variations, whereas the effect of transcriptional enhancers remains unclear due to the lack of an effective way to link enhancers with their controlled genes. Recently, we discovered a class of inter-tumor, inter-patient DNA methylation variations in putative enhancers that predict changes in gene expression levels with much greater power than promoter or sequence analyses. The overall goal of this proposal is to determine if changes in enhancer methylation form part of the genomic basis of cancer. Our aim is to elucidate methylation-influenced disease regulatory circuits that affect cancer driver and risk genes and may ultimately serve as markers for disease progression and drug response. Utilizing a new genomic methodology, which allows systematic prediction and verification of gene-enhancer pairing, I will test the above hypothesis in two disease models: breast cancer and glioblastoma. I will methodologically assess numerous potential enhancers across the disease genomes and explore the effects of genetic and epigenetic mutations and variations at these sites. Informative sites will then be evaluated as markers of gene expression level in tumor biopsies. Ultimately, I will apply novel tools to manipulate selected enhancers genetically and epigenetically, thus investigating the causal relationships between enhancer methylation and gene expression, and assessing the potential for tuning gene expression levels by enhancer methylation modification. This study may transform our understanding of the mechanisms underlying disease predisposition, determine the regulatory circuits of key disease genes, lead to improved diagnosis and predictive abilities, and may pave the way for precision epigenetic therapy.
Max ERC Funding
2 000 000 €
Duration
Start date: 2017-04-01, End date: 2022-03-31
Project acronym PICHO
Project p53 control of epithelial homeostasis
Researcher (PI) Yinon Ben Neriah
Host Institution (HI) THE HEBREW UNIVERSITY OF JERUSALEM
Call Details Advanced Grant (AdG), LS4, ERC-2011-ADG_20110310
Summary Background: Our recent studies implicate p53 in gut tissue homeostasis - suppressing epithelial invasion. This function is tightly linked to suppression of a gene cluster (PSIS- p53-Suppressed Invasiveness Signature), which requires Wnt activation and other cues, yet is only expressed upon loss of p53. The invasive signature explains a broad spectrum of the invasiveness property, from the loss of enterocyte polarity to matrix degradation, pointing to a concerted action. We documented a tight association between invasiveness and coexpression of several PSIS genes in different mouse models and showed that PSIS expression is essential in mediating epithelial cell invasiveness following p53 depletion.
Goal: Elucidate functions of p53 activation which are of particular importance for epithelial tissues. Understand how WT p53 contributes to preserving epithelial boundaries, prohibiting invasion and abnormal cell mixture and controlling stem cell dynamics under tissue stress.
Methodology: We will investigate the epithelial role of p53 and the invasive signature genes in several mouse models of inflammatory bowel diseases and intestinal cancer. These models will incorporate p53-modulating switchable genetic elements and cell-tracking genetic markers for monitoring tissue dynamics. Analyses of relevant human pathology samples will complement the mouse studies.
Significance: Invasion is a defining hallmark of malignancy and understanding early invasion of tumor cells is of fundamental importance in designing future therapies for cancer - targeting PSIS is an example. PSIS database may also be used to develop biomarkers for distinguishing malignant tumors from benign ones, a critical determinant of therapeutic options in several types of cancers, currently solely based on morphologic assessment. A molecular definition of early invasive lesions may allow early implementation of curative treatments while withholding patient overtreatment which often results in serious morbidity.
Summary
Background: Our recent studies implicate p53 in gut tissue homeostasis - suppressing epithelial invasion. This function is tightly linked to suppression of a gene cluster (PSIS- p53-Suppressed Invasiveness Signature), which requires Wnt activation and other cues, yet is only expressed upon loss of p53. The invasive signature explains a broad spectrum of the invasiveness property, from the loss of enterocyte polarity to matrix degradation, pointing to a concerted action. We documented a tight association between invasiveness and coexpression of several PSIS genes in different mouse models and showed that PSIS expression is essential in mediating epithelial cell invasiveness following p53 depletion.
Goal: Elucidate functions of p53 activation which are of particular importance for epithelial tissues. Understand how WT p53 contributes to preserving epithelial boundaries, prohibiting invasion and abnormal cell mixture and controlling stem cell dynamics under tissue stress.
Methodology: We will investigate the epithelial role of p53 and the invasive signature genes in several mouse models of inflammatory bowel diseases and intestinal cancer. These models will incorporate p53-modulating switchable genetic elements and cell-tracking genetic markers for monitoring tissue dynamics. Analyses of relevant human pathology samples will complement the mouse studies.
Significance: Invasion is a defining hallmark of malignancy and understanding early invasion of tumor cells is of fundamental importance in designing future therapies for cancer - targeting PSIS is an example. PSIS database may also be used to develop biomarkers for distinguishing malignant tumors from benign ones, a critical determinant of therapeutic options in several types of cancers, currently solely based on morphologic assessment. A molecular definition of early invasive lesions may allow early implementation of curative treatments while withholding patient overtreatment which often results in serious morbidity.
Max ERC Funding
2 500 000 €
Duration
Start date: 2012-10-01, End date: 2017-09-30
Project acronym RUBICAN
Project RNF20 and H2B ubiquitination: linking chromatin dynamics, transcriptional control and cancer
Researcher (PI) Moshe Oren
Host Institution (HI) WEIZMANN INSTITUTE OF SCIENCE
Call Details Advanced Grant (AdG), LS4, ERC-2011-ADG_20110310
Summary Chromatin modifications play a major role in regulating genome function. Perturbations in such modifications can contribute to neoplastic processes. We will focus on a specific chromatin modification: histone H2B monoubiquitylation. The significance of monoubiquitylated H2B (H2Bub) will be studied by manipulating RNF20, the major E3 ubiquitin ligase responsible for H2B ubiquitylation as part of a heteromeric complex with RNF40.
In one major line of research, we will assess the biochemistry of RNF20/H2Bub. The effects of RNF20/H2B on gene expression will be explored through identification of proteins that interact with H2Bub and through in vitro incorporation of H2Bub into nucleosomes. Effects of H2Bub on transcription elongation will be studied by a new high resolution ChIP-seq method (NET-seq). Based on recent ChIP-seq data, we will also explore links between H2B and regulation of splicing. Furthermore, we will investigate the regulatory crosstalk between H2Bub and microRNAs.
The other major line of research will explore the biology of RNF20/H2Bub, with particular emphasis on cancer-related processes. This will be addressed through a combination of cell culture models and mouse models, including constitutive and conditional RNF20 knockout mice. The contribution of RNF20/H2Bub to various differentiation programs, with particular emphasis on embryonic stem cell differentiation, will also be investigated. In addition, we will study the impact of RNF20/H2Bub on NF-kB activity and on inflammatory responses; this will combine in vitro and in vivo systems, with emphasis on inflammation-related cancer. Finally, we will monitor changes in RNF20, RNF40 and H2Bub status in human tumors and investigate underlying mechanisms.
Summary
Chromatin modifications play a major role in regulating genome function. Perturbations in such modifications can contribute to neoplastic processes. We will focus on a specific chromatin modification: histone H2B monoubiquitylation. The significance of monoubiquitylated H2B (H2Bub) will be studied by manipulating RNF20, the major E3 ubiquitin ligase responsible for H2B ubiquitylation as part of a heteromeric complex with RNF40.
In one major line of research, we will assess the biochemistry of RNF20/H2Bub. The effects of RNF20/H2B on gene expression will be explored through identification of proteins that interact with H2Bub and through in vitro incorporation of H2Bub into nucleosomes. Effects of H2Bub on transcription elongation will be studied by a new high resolution ChIP-seq method (NET-seq). Based on recent ChIP-seq data, we will also explore links between H2B and regulation of splicing. Furthermore, we will investigate the regulatory crosstalk between H2Bub and microRNAs.
The other major line of research will explore the biology of RNF20/H2Bub, with particular emphasis on cancer-related processes. This will be addressed through a combination of cell culture models and mouse models, including constitutive and conditional RNF20 knockout mice. The contribution of RNF20/H2Bub to various differentiation programs, with particular emphasis on embryonic stem cell differentiation, will also be investigated. In addition, we will study the impact of RNF20/H2Bub on NF-kB activity and on inflammatory responses; this will combine in vitro and in vivo systems, with emphasis on inflammation-related cancer. Finally, we will monitor changes in RNF20, RNF40 and H2Bub status in human tumors and investigate underlying mechanisms.
Max ERC Funding
2 500 000 €
Duration
Start date: 2012-01-01, End date: 2016-12-31
Project acronym UVdynamicsProtection
Project Aligning pigmentation and repair: a holistic approach for UV protection dynamics
Researcher (PI) Karmit Levy
Host Institution (HI) TEL AVIV UNIVERSITY
Call Details Consolidator Grant (CoG), LS4, ERC-2016-COG
Summary The human body takes different measures in order to protect itself against the results of UV exposure and its accompanied hazards, such as skin cancer. Despite extensive studies regarding the molecular regulation of the two main UV protection mechanisms, namely, the DNA repair system and the pigmentation system, a comprehensive theory that simultaneously accounts for the two systems is still missing. Hence, the ground-breaking goal of this proposal is to elucidate, for the first time, the dynamic control used to schedule and synchronize the UV protection subsystems.
Since these two systems serve the same physiological purpose, but on different time scales (DNA repair takes minutes, while pigmentation lasts hours to days), I propose to take the novel approach of focusing on their timing as an opportunity to uncover their regulation. As a first step, we exposed human and mouse skin to UV and found that UV exposure at 48hr intervals resulted in higher skin pigmentation than did exposure at 24hr intervals, even after controlling for total UV dosage. Furthermore, we found that the expression level of the melanocyte central regulator, MITF, exhibits damped oscillatory behaviour during this 48hr interval. I therefore hypothesize that the dynamic behaviour of the central regulator dictates the UV–response timing of the two protection systems. In the proposed research, I will take a holistic approach and address this issue from three complementary perspectives: (1) transcriptional dynamics, (2) temporal effects on cellular output, and (3) DNA repair after UV. This will be achieved by utilizing and developing new experimental and analytical tools that will allow us to correlate the temporal behaviours of a wide set of molecular markers. Reaching our goals will provide a breakthrough in our understanding of skin protection from UV and the underlying mechanisms that control it. These findings may offer exciting new avenues for future skin cancer prevention.
Summary
The human body takes different measures in order to protect itself against the results of UV exposure and its accompanied hazards, such as skin cancer. Despite extensive studies regarding the molecular regulation of the two main UV protection mechanisms, namely, the DNA repair system and the pigmentation system, a comprehensive theory that simultaneously accounts for the two systems is still missing. Hence, the ground-breaking goal of this proposal is to elucidate, for the first time, the dynamic control used to schedule and synchronize the UV protection subsystems.
Since these two systems serve the same physiological purpose, but on different time scales (DNA repair takes minutes, while pigmentation lasts hours to days), I propose to take the novel approach of focusing on their timing as an opportunity to uncover their regulation. As a first step, we exposed human and mouse skin to UV and found that UV exposure at 48hr intervals resulted in higher skin pigmentation than did exposure at 24hr intervals, even after controlling for total UV dosage. Furthermore, we found that the expression level of the melanocyte central regulator, MITF, exhibits damped oscillatory behaviour during this 48hr interval. I therefore hypothesize that the dynamic behaviour of the central regulator dictates the UV–response timing of the two protection systems. In the proposed research, I will take a holistic approach and address this issue from three complementary perspectives: (1) transcriptional dynamics, (2) temporal effects on cellular output, and (3) DNA repair after UV. This will be achieved by utilizing and developing new experimental and analytical tools that will allow us to correlate the temporal behaviours of a wide set of molecular markers. Reaching our goals will provide a breakthrough in our understanding of skin protection from UV and the underlying mechanisms that control it. These findings may offer exciting new avenues for future skin cancer prevention.
Max ERC Funding
1 971 875 €
Duration
Start date: 2017-04-01, End date: 2022-03-31
Project acronym WTBLDOHRNCE
Project Walking the tightrope between life and death: Oxygen homeostasis regulation in the nematode Caenorhabditis elegans
Researcher (PI) Einav Gross
Host Institution (HI) THE HEBREW UNIVERSITY OF JERUSALEM
Call Details Starting Grant (StG), LS4, ERC-2011-StG_20101109
Summary Oxygen (O2) is vital for the life of all aerobic animals. However, fine-tuned regulation of O2 levels is crucial since both shortage (hypoxia) and excess (via the production of reactive oxygen species, ROS) may be harmful. Indeed, both hypoxia and ROS may underlie the pathophysiology of many diseases such as atherosclerosis and Alzheimer’s. To understand how this fine-tuned O2 regulation is achieved at both the molecular and organismal levels my research proposal aims to explore the following integrated questions, using the nematode C. elegans as a model organism.
1) How do animal sense O2? What are the molecular sensors and how do they act together to fine-tune O2 responses?
2) How does O2 regulate food intake, and repress appetite in hypoxia?
3) How do animals survive and behaviorally adapt to hypoxia without HIF-1?
4) How hydrogen sulfide (H2S) regulates O2 responses and aging?
5) How do animals protect against mRNA oxidation damage?
I have focused my research on the globins. GLB-5 is a C. elegans hexacoordinated globin that regulates foraging behavior in response to subtle changes in O2 concentration. Like neuroglobin and cytoglobin in our brain, GLB-5 is expressed in neurons. Recently I discovered that GLB-5 regulates the re-adaptation of animals to 21% O2 after hypoxia. To understand how GLB-5 regulates hypoxia-reoxygenation responses I made a mutagenesis screen and isolated four classes of GLB-5 suppressors, and mapped them using single-nucleotide polymorphisms (SNP’s) to about a 1 Mbp genomic interval. Using a novel non-PCR based libraries preparation and Next Generation whole-genome sequencing, I have already sequenced four independent mutations and cloned one of the GLB-5 suppressors. In the future, I intend to clone more suppressor genes, and use this methodology in other parts of my project. By doing so, I aim to understand O2 homeostasis regulation at all levels; from the molecular signaling network to the physiology and behavior of the whole animal.
Summary
Oxygen (O2) is vital for the life of all aerobic animals. However, fine-tuned regulation of O2 levels is crucial since both shortage (hypoxia) and excess (via the production of reactive oxygen species, ROS) may be harmful. Indeed, both hypoxia and ROS may underlie the pathophysiology of many diseases such as atherosclerosis and Alzheimer’s. To understand how this fine-tuned O2 regulation is achieved at both the molecular and organismal levels my research proposal aims to explore the following integrated questions, using the nematode C. elegans as a model organism.
1) How do animal sense O2? What are the molecular sensors and how do they act together to fine-tune O2 responses?
2) How does O2 regulate food intake, and repress appetite in hypoxia?
3) How do animals survive and behaviorally adapt to hypoxia without HIF-1?
4) How hydrogen sulfide (H2S) regulates O2 responses and aging?
5) How do animals protect against mRNA oxidation damage?
I have focused my research on the globins. GLB-5 is a C. elegans hexacoordinated globin that regulates foraging behavior in response to subtle changes in O2 concentration. Like neuroglobin and cytoglobin in our brain, GLB-5 is expressed in neurons. Recently I discovered that GLB-5 regulates the re-adaptation of animals to 21% O2 after hypoxia. To understand how GLB-5 regulates hypoxia-reoxygenation responses I made a mutagenesis screen and isolated four classes of GLB-5 suppressors, and mapped them using single-nucleotide polymorphisms (SNP’s) to about a 1 Mbp genomic interval. Using a novel non-PCR based libraries preparation and Next Generation whole-genome sequencing, I have already sequenced four independent mutations and cloned one of the GLB-5 suppressors. In the future, I intend to clone more suppressor genes, and use this methodology in other parts of my project. By doing so, I aim to understand O2 homeostasis regulation at all levels; from the molecular signaling network to the physiology and behavior of the whole animal.
Max ERC Funding
1 495 922 €
Duration
Start date: 2011-11-01, End date: 2017-10-31
